Top of this page
Skip navigation, go straight to the content

Clinical Studies Clinical studies index Rozanolixizumab - UCB7665
 

Rozanolixizumab (UCB7665)

Disease area
studied
Abbreviated title Phase Study ID Registry database Study results Lay summary Publication (if available)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Phase 2 CIDP01
Ongoing
Chronic Inflammatory Demyelinating Polyradiculoneuropathy A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Phase 2 CIDP04 
Ongoing
Myasthenia Gravis A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis Phase 2 MG0002
Completed
NCT03052751
2016-002698-36
Bril V., Neurology 2019; 92(15 suppl.), abs S43.001
Myasthenia Gravis A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Phase 3 MG003
Ongoing
Myasthenia Gravis A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Phase 3 MG0004
Ongoing
NCT04124965
Thrombocytopenia Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia Phase 2 TP0001
Completed
NCT02718716
2015-003984-12
Robak T., Jarque I., Musteata V., Kiessling P., Massow U. et al. Hemasphere 2018; 2(suppl.2):284–5. 23rd Congress of the European Hematology Association, EHA 2018; Stockholm, Sweden